In the Aug. 17 issue of the Journal of the National Cancer Institute, a team of researchers reports that non-small cell lung cancer tumor cells with common mutations respond much better to AstraZeneca's Iressa than to Erbitux, which is manufactured by ImClone Systems and Bristol-Myers Squibb.

The study's results are not entirely surprising, since Iressa binds to the intracellular tyrosine-kinase domain of EGFR, where the mutations are expressed, while Erbitux binds the receptor's extracellular ligand-binding site.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.